Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $42.33 Average Price Target from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received an average recommendation of “Buy” from the five ratings firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $42.3333.

COLL has been the subject of several recent analyst reports. HC Wainwright raised shares of Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price objective for the company in a report on Monday, August 11th. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Saturday, September 27th. Finally, Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Thomas B. Smith sold 17,478 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $38.42, for a total value of $671,504.76. Following the completion of the sale, the executive vice president owned 70,264 shares of the company’s stock, valued at $2,699,542.88. This trade represents a 19.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Scott Dreyer sold 16,389 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $38.21, for a total value of $626,223.69. Following the transaction, the executive vice president directly owned 103,613 shares in the company, valued at approximately $3,959,052.73. This represents a 13.66% decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,792 shares of company stock valued at $2,084,207 over the last three months. 2.51% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COLL. CWM LLC raised its holdings in Collegium Pharmaceutical by 453.9% during the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 1,153 shares during the last quarter. Wealthquest Corp acquired a new stake in shares of Collegium Pharmaceutical during the 1st quarter worth approximately $62,000. EverSource Wealth Advisors LLC raised its stake in shares of Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after buying an additional 2,190 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Collegium Pharmaceutical by 368.9% during the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock worth $82,000 after buying an additional 2,169 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in Collegium Pharmaceutical by 304.6% in the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 2,294 shares during the period.

Collegium Pharmaceutical Stock Up 1.0%

COLL opened at $34.61 on Friday. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 33.28 and a beta of 0.65. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.10 and a current ratio of 1.18. The firm’s 50-day simple moving average is $35.94 and its 200-day simple moving average is $31.56. Collegium Pharmaceutical has a twelve month low of $23.23 and a twelve month high of $42.29.

Collegium Pharmaceutical declared that its Board of Directors has authorized a share buyback program on Monday, July 7th that authorizes the company to repurchase $150.00 million in shares. This repurchase authorization authorizes the specialty pharmaceutical company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.